Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Pharmacyclics Posts Bigger First Quarter Loss on Stock Costs

By Pharmaceutical Processing | May 1, 2013

Cancer drug developer Pharmacyclics Inc. said Wednesday that it had a bigger loss in the first quarter as its costs increased.

Pharmacyclics said costs increased with the timing of stock option grants, growth in its share price, and hiring employees. The company is developing the cancer drug ibrutinib with a unit of Johnson & Johnson. Its share price has nearly tripled in value over the last year, and it has hired about a third of its employees over the last six months of 2012.

Pharmacyclics said it lost $51.9 million, or 73 cents per share, in the latest quarter, after a loss of $12.8 million, or 19 cents per share, in the first quarter of 2012. It lost 40 cents per share in the most recent quarter, if one-time items are excluded, compared with 14 cents per share a year ago. Revenue rose to $2.8 million from $1.9 million.

Analysts expected a loss of 17 cents per share and $2.5 million in revenue, according to FactSet.

Pharmacyclics doesn’t have any approved drugs. With Janssen Biotech it is conducting clinical trials of ibrutinib as a treatment for chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

The company said its stock-based compensation costs grew by about $20 million to $23.6 million compared to a year ago.

In early April Janssen paid Pharmacyclics $50 million after it enrolled the fifth patient in a late-stage trial of ibrutinib as a treatment for chronic lymphocytic lymphoma and small lymphocytic lymphoma. As a result of that payment the company said it will be near break-even for the second quarter and the full year.

Shares of Pharmacyclics fell $5.25, or 6.4 percent, to $76.25 on Wednesday. Prior to that decline the stock had tripled in value over the last 12 months.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE